Meiragtx Holdings plc key statistics and ratios
In fiscal 2025, Meiragtx Holdings plc had an operating margin of -130.2% and a current ratio of 0.75. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | −438.4% | −401.9% | −193.0% | −730.9% | −977.8% | −493.4% | −130.2% | 46.3% |
| Net margin | −411.9% | −372.6% | −211.0% | −814.2% | −599.5% | −444.1% | −140.3% | 19.9% |
| Free-cash-flow margin | 83.2% | −545.5% | −150.9% | −741.6% | −895.6% | −328.9% | −61.7% | 2.6% |
| Return on equity | −28.7% | −27.0% | −37.5% | −85.5% | −65.7% | −143.5% | — | 75.2% |
| Return on assets | −16.9% | −16.9% | −23.3% | −40.6% | −26.1% | −49.6% | −44.4% | 24.6% |
| Asset turnover | 0.04 | 0.05 | 0.11 | 0.05 | 0.04 | 0.11 | 0.32 | 1.24 |
| Current ratio | 5.47 | 5.03 | 2.69 | 1.88 | 2.38 | 2.03 | 0.75 | 3.76 |
| Debt to equity | 0.0% | 0.0% | 0.5% | 60.3% | 52.2% | 108.0% | — | 46.3% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m | n/m | 14.7x |
| R&D as % of revenue | 187.1% | 217.9% | 176.9% | 538.5% | 740.4% | 359.0% | 159.3% | 38.5% |
| Capital spending as % of revenue | 67.6% | 134.4% | 122.9% | 282.4% | 143.9% | 14.9% | 4.7% | 0.8% |
| Free cash flow ÷ net income | — | — | — | — | — | — | — | 13.3% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | −367.0% | −147.2% | <−999% | <−999% | <−999% | 35.1% | <−999% | 76.0% |
| Net margin | −360.5% | −184.2% | <−999% | <−999% | <−999% | 20.0% | <−999% | 50.0% |
| Free-cash-flow margin | −236.0% | −114.5% | <−999% | <−999% | <−999% | 61.5% | >999% | −12.1% |
| Current ratio | 2.34 | 2.03 | 1.53 | 0.88 | 0.22 | 0.75 | 0.55 | 3.76 |
| Debt to equity | 76.2% | 108.0% | 222.0% | >999% | — | — | — | 46.3% |
| R&D as % of revenue | 240.5% | 112.1% | >999% | 907.5% | >999% | 40.9% | >999% | 18.0% |
Financial health
- Short-term assets cover short-term liabilities $218m of assets due within a year against $58m of liabilities due within a year.
- Short-term assets cover long-term liabilities $218m short-term assets against $123m of longer-dated liabilities.
- More cash than debt $143m of cash against $100m of debt.
- Debt below 40% of shareholders' equity Debt is 46% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt $14m of operating cash flow against $100m of debt.
- Operating profit covers interest at least five times over Operating income of $184m against $12m of interest.
Moat
Weak moat
How hard Meiragtx Holdings's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -34.9% of total assets over 9 years.
- Durability 10 / 20
Operating margin has been a median -345.1%; its worst year was -2083.2%.
- Cash conversion 1 / 20
Free cash flow was positive in 1 of 7 years, at a median -403.0% of revenue.
- Discipline 0 / 20
The diluted share count rose 103.9% over five years; stock-based pay has been a median 95.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).
Compare with peers
- Mannkind Corp statistics
- Sinovac Biotech LTD statistics
- Novavax Inc statistics
- Pharming Group N.V. statistics
- Ardelyx, Inc. statistics
Head to head: MGTX vs MNKDMGTX vs SVAMGTX vs NVAXMGTX vs PHAR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies